` PEB (Pacific Edge Ltd) vs NZX All Share Comparison - Alpha Spread

PEB
vs
NZX All Share

Over the past 12 months, PEB has significantly outperformed NZX All Share, delivering a return of 43% compared to the NZX All Share's 4% drop.

Stocks Performance
PEB vs NZX All Share

Loading

Performance Gap
PEB vs NZX All Share

Sign Up to see
Performance Gap
Sign In
Sign Up

Performance By Year
PEB vs NZX All Share

Loading
PEB
NZX All Share
Add Stock

Competitors Performance
Pacific Edge Ltd vs Peers

NZX All Share
PEB
ABBV
AMGN
GILD
VRTX
Add Stock

Pacific Edge Ltd
Glance View

Market Cap
97.4m NZD
Industry
Biotechnology

Pacific Edge Ltd. engages in the discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring of cancer. The firm develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers. The firm's segments include NZ Laboratory, US Laboratory and Research NZ & Australia. Its segments are engaged in the research and development of diagnostic and prognostic products for human cancer both in New Zealand and Australia, and operation of the laboratories used for the detection of bladder cancer in the United States and New Zealand. The company offers Cxbladder, which is a suite of non-invasive laboratory tests for the detection and the management of bladder cancer. Cxbladder includes a suite of urine-based molecular tests to determine the likelihood of bladder cancer in patients presenting with hematuria. Its pipeline includes Cxcolorectal, which is a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancer, enabling prediction of aggressiveness of the tumor.

PEB Intrinsic Value
HIDDEN
Show
Back to Top